On October 27, 2026, nine insiders at Lycia Therapeutics, Inc. (LYCA) executed significant stock purchases, collectively acquiring approximately $315 million worth of shares. The transactions occurred at a price of $18.00 per share.
Among the notable buyers were entities associated with Venrock and VHCP, including Healthcare Capital Partners Eg, L.P. Venrock, Healthcare Capital Partners Xp, L.P. Venrock, Management Xp, Llc Vhcp, Management Eg, Llc Vhcp, Co-Investment Holdings Iii, Llc Vhcp, Management Iii, Llc Vhcp, and Healthcare Capital Partners Iii, L.P. Venrock. Individual insiders Nimish P. Shah and Bong Y. Koh also participated in the buying activity.
This coordinated buying by multiple insiders is often interpreted as a strong bullish signal, suggesting confidence in the company's future prospects. The total volume of shares purchased across these transactions was substantial, reflecting a significant commitment from key stakeholders within Lycia Therapeutics.